Sarepta (SRPT) shared the following update related to Elevidys, the only approved gene therapy for patients with Duchenne muscular dystrophy. The company received feedback from the Medicines & Healthcare products Regulatory Agency in the United Kingdom that dosing may continue uninterrupted in ENVISION, study SRP-9001-303.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Buy Rating on Sarepta Therapeutics: Valuation Disconnect and Growth Potential Highlighted by Elevidys Approval
- Sarepta price target lowered to $84 from $169 at JPMorgan
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations
- Sarepta reports positive ELEVIDYS protein expression data in young patients
- Sarepta presents EMBARK study data at ASGCT conference